2023 Biotechnology Industry Innovation Forum 5 month 25 On 2023 The Biotechnology Industry Innovation Forum and the New Product Release Conference of Zhongshan Bio's Sterile Sodium Hyaluronate was successfully held at the Beijing National Convention Center. The forum was themed 'New Forces in Sterility, Leading the New Future', and focused on exchanges and discussions on policy regulations, R&D innovation, and industry trends in fields such as biotechnology, bio-manufacturing, and biomedicine.   At the same time, Frost & Sullivan Frost & Sullivan Frost & Sullivan, in collaboration with Zhongshan Biology, jointly released the 'China Aseptic Grade Hyaluronic Acid White Paper' (hereinafter referred to as the 'Report'). Yang Lizhu, the consulting director for Frost & Sullivan Greater China, was invited to attend the event and provided an in-depth interpretation of the report at the press conference. The 'White Paper on Chinese Aseptic-grade Hyaluronic Acid' (hereinafter referred to as the 'Report') was jointly released by Frost & Sullivan and Zhongshan Biotechnology. The report delves into four major chapters: the hyaluronic acid raw material industry, Chinese aseptic-grade hyaluronic acid raw materials, end-use applications of aseptic-grade hyaluronic acid, and the market competition landscape of aseptic-grade hyaluronic acid raw materials. It aims to interpret the current development status and prospects of the aseptic-grade hyaluronic acid industry from a scientific, rational, and professional analytical perspective. Frost & Sullivan Greater China Consulting Director Yang Lizhu   Yang Lizhu pointed out that China is the world's largest producer and seller of hyaluronic acid raw materials, with its fermentation technology level, production volume, and quality all reaching international advanced standards.   According to the research data from Frost & Sullivan, 2022 The total sales volume of hyaluronic acid raw materials in China accounted for 82.7% Chinese enterprises rank at the top of global sales volumes, while overseas enterprises account for a smaller proportion of hyaluronic acid raw material sales.   COVID-19 pandemic It has had a short-term impact on both the supply and demand sides of the global hyaluronic acid raw material market. However, encouraged by policies in China's import and export trade market, the sales volume of China's hyaluronic acid raw material market in the past 5 Maintains continuous growth annually, from 2017 year 26.5 RMB 10 billion, an increase of 2022 year 39.0 RMB 10 billion, with an annual compound growth rate of 8.0% . Looking at hyaluronic acid raw materials from different grades, 2022 The sales volume of cosmetic-grade hyaluronic acid raw materials accounted for the highest proportion, followed by pharmaceutical-grade raw materials. 3.6% However, the export price of pharmaceutical-grade hyaluronic acid raw materials in China is about 2,700 - 25,000 US dollar / kilograms, for other levels it is approximately 150 - 500 US dollar / kilograms.   Due to the high cost, pharmaceutical-grade raw materials have a significant profit margin advantage. The report shows that due to China 2021 The policy dividend released at the beginning of the year regarding food-grade hyaluronic acid has led to a rapid short-term growth in sales of food-grade hyaluronic acid raw materials. It is expected that over the next five years, the Chinese hyaluronic acid raw material market will maintain 8.4% The high compound growth rate, in 2027 Annual achievement 58.2 RMB 10 billion. Source: Analysis by Frost & Sullivan   Yang Lizhu then briefly introduced the aseptic-grade hyaluronic acid raw material and its advantages.   Sterile-grade sodium hyaluronate raw materials will become the preferred choice for customers producing sterile preparations and sterile medical devices using non-final sterilization processes.   Sterile grade hyaluronic acid raw materials refer to non-final sterilized hyaluronic acid raw material products produced through aseptic manufacturing processes. The process design for non-final sterilized products uses aseptic filtration to remove bacteria, ensuring product quality through strict aseptic control. Sodium hyaluronate is sensitive to high temperatures and decomposes significantly under moist heat sterilization conditions, causing significant fluctuations in product viscosity before and after sterilization, resulting in products that do not meet quality standard requirements. For manufacturers of sterile preparations and sterile medical devices that cannot be finally sterilized, using sterile raw materials eliminates the risk of viscosity degradation during material sterilization, avoiding experimental costs and time costs.   Currently, the market for sterile-grade sodium hyaluronate raw materials is still in its infancy, with no mature or large-scale sterile production lines in place, and there is still a distance to go before mass production and sales can be achieved.   Since the end-use applications of sterile-grade hyaluronic acid raw materials are similar to those of pharmaceutical-grade hyaluronic acid raw materials, the market scale of pharmaceutical-grade hyaluronic acid raw materials can be used to predict the downstream demand for sterile-grade raw materials. Pharmaceutical-grade hyaluronic acid raw materials are generally used in drug treatment or medical aesthetics. Due to the special nature of their use, the overall performance requirements for products are high, and they need to be NMPA Authentication is required for use, so the price is also higher. The report shows, 2022 The market scale of pharmaceutical-grade hyaluronic acid raw materials in China in 21.6 tons 2017 - 2022 Annual compound growth rate 11.6% expected 2022 - 2027 Annual compound growth rate 11.4% , achieved 37.1 tons.   Similarly, the downstream applications of sterile-grade hyaluronic acid raw materials are mainly in the pharmaceutical field. Due to their higher product quality requirements, production process requirements, and qualification standards, the expected selling price will be higher than that of pharmaceutical-grade raw materials.   In the future, it is expected that sterile-grade hyaluronic acid raw materials will replace a portion of the market share for pharmaceutical-grade hyaluronic acid raw materials. Due to the special properties of cross-linked hyaluronic acid, such as good biocompatibility, longer degradation time in vivo, and effective filling and shaping effects, it has become the mainstream soft tissue filling material and is gradually replacing other fillers such as collagen. It is widely used in various plastic surgery fields. Yang Lizhu said,   With the continuous improvement of domestic enterprises' technology and craftsmanship levels, local hyaluronic acid companies in the medical beauty sector are increasingly competing with foreign brands both domestically and even in the international market, leading to a gradual increase in the sales volume of domestic hyaluronic acid fillers for medical beauty applications. Compared to surgical plastic surgery, non-surgical minimally invasive medical aesthetics represented by injections have a faster recovery time, lower costs and risks, thus enjoying a higher market acceptance and repeat purchase rate. 2022 In [year], the market scale of hyaluronic acid end-products for medical aesthetics in China was larger than that of other medical end-application areas, reaching 77.7 RMB 10 billion, 2017 - 2022 Annual compound growth rate 19.9% , and is expected to be 24.9% The compound growth rate is at 2027 Annual achievement 236.6 RMB 10 billion. Source: Analysis by Frost & Sullivan     In addition,   In the field of orthopedics, hyaluronic acid can be used for the treatment of bone and joint diseases, fracture fixation, joint stiffness, and injections for lumbar discectomy.   It is estimated that the market scale of hyaluronic acid end-products for orthopedic treatment in China will be 2027 reaching about 18.4 Yuan, with a compound annual growth rate of 6.0% In the field of ophthalmology, hyaluronic acid end-products include hyaluronic acid adhesives used in ophthalmic surgeries (cataract surgery, intraocular lens implantation, penetrating keratoplasty, glaucoma surgery, removal of intraocular foreign bodies, ocular trauma surgery, etc.) and hyaluronic acid artificial tears for treating symptoms such as dry eye syndrome. In the future, it is expected that the overall market size of hyaluronic acid products for ophthalmic treatment in China will further expand, estimated 2027 reaching about 52 RMB 10 billion.   The report shows that Zhongshan Biotechnology is the first company in China to launch sterile-grade sodium hyaluronate raw materials produced by aseptic production lines. Zhongshan Biotechnology's sterile-grade sodium hyaluronate raw materials meet the terminal application standards of the downstream pharmaceutical industry.   The Eighth Workshop of Zhongshan Biotechnology is an automated workshop specializing in the production of sterile hyaluronic acid raw materials and is also the first sterile sodium hyaluronate workshop in China. The equipment in this workshop is selected and used with production equipment from first-class domestic and international enterprises. From the source of material transfer, full-process airtight operation is adopted, and the production line is fully automated, meeting the production standards for sterile-grade sodium hyaluronate raw materials. Compared with traditional pharmaceutical-grade raw material production workshops, Zhongshan Biotechnology's sterile production workshop has stricter quality control, with higher requirements for production equipment, process technology, and production environment.   Based on research into China's sterile-grade hyaluronic acid industry, Frost & Sullivan has confirmed that Shandong Zhongshan Biotechnology Co., Ltd. is the pioneer of sterile-grade sodium hyaluronate. At this forum, Yang Lizhu presented a market position confirmation certificate to Shandong Zhongshan Biotechnology Co., Ltd. Yang Lizhu, consulting director of Frost & Sullivan Greater China region (left), presented the certificate to Cui Hu, founder of Zhongshan Biosciences (right). Recommended Reading

2022 The global economy in 2023 exhibited a stagflationary trend characterized by high inflation and low growth. The supply and demand structure of the butanol, phthalic anhydride, and plasticizers markets continued to change, with plasticizer prices constantly breaking new lows within the year. Outlook 2023 - 2025 In [year], China's butanol industry began to see new production capacity gradually coming online, but the downstream plasticizer industry continues to face the problem of overcapacity, marking the start of a new round of challenges. 2023 What changes will occur in supply in the year? Faced with high cost pressures, can plasticizer companies make process improvements to reduce energy consumption and thereby reduce cost pressure? Can the domestic and international economic environment improve, and can the industrial supply-demand gap narrow? As octanol products gradually expand capacity, it can provide for the future 3 - 5 What opportunities and challenges does the annual market bring? With macro development direction and various questions about industrial supply and demand, 5 month 17 day -19 On the day, the 10th Ding-xin alcohol conference, hosted by Longzhong Information - phenyl anhydride - The Plastics Additive Industry Conference was successfully held in Xiamen, Fujian. The conference brought together the most comprehensive enterprises in the industry chain related to butylene-butanol, o-xylene, phthalic anhydride, plastics additives, and plastic products from across China to exchange on the current development status and future prospects of the industry; industry experts from crude oil, plastic products, and other sectors were specially invited to interpret industry hot topics, comprehensively understand macro policies and current terminal demand situations, and pave the way for the development of the industry chain. Frost & Sullivan Frost & Sullivan Cai Yufan, consulting manager of Frost & Sullivan's Greater China region, was invited to attend the meeting and delivered a presentation on   Development Trends of Disposable Gloves Market and Plasticizer Market    Give a speech. Consulting Manager, Greater China, Frost & Sullivan Cai Yufan Cai Yufan made a brief analysis of the global market, export market, and raw material market for disposable gloves. She stated,   After the emergence of COVID-19 variants, global cases surged significantly. The domestic epidemic situation is complex, and while accelerating inventory consumption, there has been a renewed demand for disposable gloves, driving the steady growth of the glove market.    Entering the post-pandemic era, the disposable glove market has gradually returned to normal. The supply and demand relationship and market environment have changed, leading to reduced corporate revenues and profits. Some small and medium-sized manufacturers that entered the market during the pandemic will be gradually phased out. However, with the improvement of people's health awareness, it is expected that market demand will experience permanent growth, and the market will continue to maintain stable growth in the future. Looking at the entire one-time glove export market in China, under the influence of tariff policies, it is evident that the export volume of disposable nitrile gloves to the United States has dropped sharply. Meanwhile, the European Union is still within the tariff exemption period. The demand for gloves in the huge medical markets of various countries continues to grow steadily, and related markets still need further observation. The data shows, 2020 During the strict epidemic control phase of the year, overseas demand surged. At the same time, China took the lead in resuming work and production in an orderly manner, securing a large number of orders and significantly increasing exports; 2021 As the epidemic improved in the year, foreign epidemic prevention policies were relaxed, and the demand for gloves gradually decreased. The market is in a stage of digesting inventory, with fewer new orders and exports starting to decline; 2022 The industry began to return to pre-pandemic levels at the beginning of the year, returning to normal; 2023 As inventory was fully digested, the industry gradually warmed up, with orders steadily increasing slightly. "Looking at the export sales of disposable gloves in China, the total export amount is in 2021 year Q1 quarter "After peaking, affected by factors such as changes in supply and demand relationships, the average selling price of disposable gloves began to decline. Although the total export amount has been significantly adjusted, it has gradually stabilized, and the export market has shown a diversified trend." Cai Yufan said. "The international situation is volatile, crude oil prices continue to fluctuate downward, and the cost pressure on nitrile gloves has been alleviated."    Cai Yufan further explained that, among the costs of nitrile gloves, nitrile latex   As the most critical raw material for the production of nitrile gloves,   accounting for more than 45% Expenditures, most glove manufacturers use external procurement channels, and their price trends directly affect the profits of downstream nitrile gloves; raw materials such as butadiene and acrylonitrile, which are used in the upstream, belong to bulk petrochemical products, and fluctuations in upstream crude oil prices will be transmitted to the glove industry. from PVC The cost of gloves, PVC Total paste resin and plasticizer PVC Glove costs are nearly 50% . PVC The output of paste resin is about 27% Used in glove production, driven by the pandemic PVC Demand for paste resin glove material, driving PVC The price of paste resin has dropped back after a significant increase. 2022 Since [start year], the overall price focus has shifted downward, currently at approximately 8,500 yuan / tons.    with DINP , DOTP The trend of plasticizers, represented by this indicator, has been stable with a slight increase. Currently, prices have not returned to the levels from two years ago, and overall supply is relatively abundant. Cai Yufan pointed out that plasticizers in PVC Glove making plays a crucial role, PVC The essence of resin is hard and brittle, but the addition of plasticizers can change this. PVC The physical properties of resin make it soft and elastic, facilitating its processing into glove materials. at PVC In glove manufacturing, the type, amount added, and usage method of plasticizers have a significant impact on the performance, appearance, and service life of gloves. If used improperly, they can lead to problems such as material deformation, aging, and cracking, affecting the service life and safety performance of the gloves. Therefore, manufacturers need to select appropriate plasticizer types and amounts based on different glove uses and requirements to ensure that the quality and safety performance of the gloves meet the standards. since 2003 Since the beginning of the year, countries and regions such as the EU and the US have begun to restrict the use of phthalates, mainly in areas such as children's toys, medical supplies, food contact materials, and cosmetics. As the scope of phthalate plasticizers is expanded, the demand for environmentally friendly plasticizers will continue to grow.   Cai Yufan believes that the environmental friendliness of plasticizer products will become an important development trend in the industry in the future.

The First Overseas Research Conference on Medical Devices 5 month 14 day after tomorrow 17 Today, with “Innovative Technology · Leading the Future " themed, lasting 4 day 87 China International Medical Devices Expo (abbreviation: CMEF ) successfully concluded at the Shanghai National Convention and Exhibition Center. This session CMEF Gathered nearly the entire domestic and international industrial chain 5000 Home exhibitors showcased tens of thousands of cutting-edge products, with over a thousand academic experts and opinion leaders participating in nearly a hundred sessions. MEDCONGRESS Academic forums have become a frontier for trend dissemination and opinion collision, including various medical institutions, distributors, and more. 22 Ten thousand industry professionals attended the event for business exchanges and cooperation talks. Relying on top-notch resources, this event is nearly 32 The ten-thousand-square-meter grand event, "Aircraft Carrier," showcased the strong vitality of a comprehensive economic recovery and the surging momentum of the medical device industry to the entire industry and society in Shanghai, this capital of science and innovation, with its bustling live effects.   In the era of the pandemic, due to considerations for public health and personal well-being, public acceptance and awareness of medical devices have been widely enhanced. The overseas exploration for gold for Chinese medical device companies has quietly begun, with a plethora of manufacturers offering a diverse range of products. With the arrival of the post-pandemic era, global markets and patient needs continue to change. How to take effective actions in response to the current situation is a question that every company seeking a second growth curve must face.    To help many customers resolve these doubts,    Frost & Sullivan, Junlian Capital, IMQ De Kai, CSA The First Overseas Research Conference on Medical Devices, with the support of Dahongyi, is 5 month 15 The event was successfully held on the day    This conference focused on the entire process of medical device going global, including how to empower R&D with digital and intelligent cloud services, how to effectively conduct overseas clinical trials, an in-depth yet easy-to-understand analysis of regulatory policies and access paths for different destinations and products, and trend analysis in the internationalization process of enterprises. It provided industry practitioners with the clearest roadmap for going global at present.   The meeting is chaired by Dr. Huang Jinglu, Vice President of Investment at Junlian Capital, and will be divided into 10 Theme of the event 1 At the roundtable forum, guests took turns to share and discuss.    Frost & Sullivan Frost & Sullivan, hereinafter referred to as 'Frost & Sullivan' Mao Hua, Partner and Managing Director of Greater China, was invited to deliver a keynote speech on "The Current Situation and Development Trends of Medical Devices Going Global in China" and participate in the roundtable forum titled "Discussing the Development Opportunities of Medical Devices Going Global". Partner and Managing Director, Greater China, Frost & Sullivan fattening Mao Hua interpreted the globalization of the medical device market from a capital perspective.   Through the analysis of multiple dimensions of the industry, the current situation and development trends of the entire chain of medical device exports were presented to the participants, as well as an overview of Chinese medical devices License-out of the Mainland The current situation has been summarized and sorted out.    He said,    A larger overseas market will gradually become an important strategic layout for domestic medical device companies.   Judging from current data, the proportion of overseas sales of global leading medical device companies is much higher than that of domestic players. Abroad Top 5 Medical device enterprise 2022 Annual income exceeds 50% From overseas, and China Top 5 In addition to Jiuan Medical Devices, the products of other medical device companies are mainly sold domestically.    Mao Hua believes that if domestic medical device companies want to become global leaders, they should consider overseas markets as an important strategic development layout for their enterprises.   On the one hand,    The full normalization of centralized procurement is inevitable. The normalization of centralized procurement squeezes profit margins, and the product prices of many brands fall on the same level. Enterprises will face the dual dilemma of significant profit compression and more intense competition. Against this backdrop,    Adjusting business layout and emphasizing overseas markets may bring new profit growth points to the enterprise; on the other hand, in recent years    The state has continuously introduced favorable policies to promote the development of innovative medical devices, continuously enhancing the R&D capabilities of enterprises, further strengthening their overseas competitiveness, and making the industry increasingly mature.   Mao Hua pointed out that driven by the epidemic, China's medical device exports IVD With the proportion increasing, domestic high-end medical devices are gradually gaining international recognition. Currently, it is an excellent time for Chinese medical device companies to go global.   Enterprises need to conduct thorough research on the market capacity and related data in overseas regions, choose the right outbound model and region based on their own circumstances, and implement localization execution strategies; they should also do a good job in product positioning analysis and market analysis, make strategic layouts for the entire lifecycle of products, adhere to long-termism and a global perspective, and build a systematic and international business system.   Swipe left and right to view more photos from the event After experts from various fields shared and discussed the business scenarios of medical devices going global, the conference kicked off the roundtable forum session titled 'Discussing Development Opportunities for Medical Devices Going Global'.     Mao Hua & Junlian Capital's Managing Director, Zhou Min, and Puren Securities CEO Meng Zhu, Li Jian, Chief Medical Industry Director of Amazon Web Services Greater China, and Luo Shan, Marketing Director of the National Innovation Center,   Views and insights are expressed on the issues encountered by medical device-related enterprises in their overseas expansion, including capital, R&D, access, regulation, and market aspects. At the same time, active discussions are held on how to enhance product global competitiveness and achieve sustainable development under the current industry development trend.   At the same time, at the conference site, the guests also answered questions from the participants regarding business issues and trend judgments in the practical operation of medical device products going global.   About Frost & Sullivan's Healthcare Practice   The Healthcare Practice of Frost & Sullivan has professional analytical capabilities and extensive project experience in the life sciences field. Leveraging the global think tank resources of Frost & Sullivan and its cross-industry business development platform in Greater China, Frost & Sullivan Healthcare has unique core advantages in healthcare industry investment and financing services. Frost & Sullivan Healthcare has a wide range of corporate clients in China and in the past 20 In the year, a vast customer network was established, and a wealth of project experience in various medical sub-fields was accumulated. Project types include Knowledge Center projects (in-depth content, promotional activities). Pre-IPO financing project DCF model Valuation, Business Plan Services), IPO listing We provide listed projects (industry consulting, clinical audits, fundraising and investment writing), market research, market value management and strategic consulting. We also cooperate with well-known domestic and international information platforms and investment and financing institutions, offering one-stop solutions for enterprises in specialized fields such as pharmaceuticals and medical devices, which has attracted widespread attention from investors.

Suncar Technology Group (Stock Code: NASDAQ:SDA ) (Abbreviated as 'Prosperous Times Alliance') was launched in 2023 year 5 month and Goldenbridge Acquisition Limited The merger was officially completed and is now 5 month 18 Daily Pass SPAC The company is listed on NASDAQ. The Group is a leading digital enterprise in China, providing automotive after-sales services and online auto insurance intermediaries. Frost & Sullivan Frost & Sullivan, Frost & Sullivan, referred to below as the 'Frost & Sullivan Team', provides exclusive industry advisory services for the listing of Shengshi Dalian. Cai Jinfeng, Executive Director of Frost & Sullivan Greater China, and Zhou Mingzi, Consulting Director, were invited to attend the group's listing ceremony. At the same time, Zhou Mingzi shared her insights into the Chinese aftermarket industry, with the presentation theme being '   Under the opportunities of new energy, China's after-sales service has evolved from 'cornering the curve' to global delivery of 'Chinese value'.   "> Frost & Sullivan Greater China Consulting Director Zhou Mingzi According to a study by Frost & Sullivan, as of 2022 At the end of the year, China's automobile ownership has exceeded 3 100 million vehicles, and the number will continue to grow steadily in the future. It is expected that by 2026 The year is about to break through 4 100 million vehicles.   Zhou Mingzi pointed out that China is the core consumer market for the global automotive market in the future and one of the core drivers of growth. The huge automobile ownership means that the broad prospects of China's after-sales service market will remain long-term, offering great market business opportunities.   Meanwhile, as of 2022 In [year], the average age of passenger cars in China has exceeded 6 In the year, the average vehicle maintenance cost for that year reached 6,000 Yuan, and the proportion of passenger car renewals exceeds 70% This indicates that China's automotive service consumption demand has reached a golden period, with stable demands for regular maintenance, repairs, and beauty services. The market is broad, providing opportunities for non- 4S The after-sales service of the store system brings huge market opportunities. Judging from past market research, when the vehicle age exceeds 5 year, 4S The churn rate of branded stores has basically reached 90% As mentioned above, the vast aftermarket service market will be undertaken by third-party independent professional service institutions. Currently, China's broad-based aftermarket service market is already approaching 6 Trillion yuan, among which the automotive maintenance, auto insurance, and used car trading sectors all possess market commercial spaces reaching the trillion level.    Zhou Mingzi stated that, driven by the continuous advancement of automotive vehicle structures and insurance coverage in China, the Chinese after-sales service market will continue to maintain steady growth. "While the Chinese after-sales service market is showing steady growth, we also see that global automotive services are undergoing changes and innovation, especially against the backdrop of the rapid popularization of new energy electric vehicles." Zhou Mingzi further explained that under the historical opportunities of new energy vehicle development, China's automotive industry has achieved 'curve overtaking' through 'smart manufacturing'. China's influence has been continuously enhanced, bringing important trends and guidance to the future development pattern of the after-sales market. Taking pure electric passenger vehicles as an example, China is not only the world's largest sales market but also contributes more than half of the global new vehicle sales. Looking at the specific data, 2022 In China, the sales volume of new energy passenger vehicles in 600 Ten thousand units, accounting for more than 25% , is expected to arrive 2025 The proportion of annual revenue will further increase to 50% .    Zhou Mingzi believes that the rapidly growing new energy vehicle market brings greater business opportunities to the after-sales service market, while also posing new requirements for it. If enterprises can seize the business opportunities brought by the new energy vehicle market, they often achieve business innovation and realize a second growth curve.   Zhou Mingzi stated that China, as the market with the fastest development and application of new energy vehicles globally at present, has the richest understanding and market experience in the new energy vehicle industry. It possesses the strongest industrial service innovation drive in the world. It is believed that the value of the global after-sales service market will be reshaped and redefined by China in the future. After a long period of research and comparison, Frost & Sullivan believes that whether it is an asset-intensive B2B Are fulfilled-taste players still light-asset players? B2B Ecological players tend to be able to B2B Starting from business needs, delving into terminal operations enables us to accurately grasp future market trends. Moreover, from a long-term competitive perspective, B2B Players are at the core of the industrial chain, capable of not only effectively B2C The service model has low business trial-and-error costs and possesses extremely high potential for upstream and downstream integration, thereby establishing a stronger business ecosystem. "Frost & Sullivan believes that current market leaders have greater potential to develop from a vehicle after-sales service ecosystem to a comprehensive automotive service ecosystem, and that they B2B The stronger the genes of a service, the better it is able to embrace market opportunities and establish itself in the domestic market, thereby exporting 'Chinese value' globally. ' Zhou Mingzi said.

Distance from Hong Kong stocks “ 18A "The implementation of the listing rules has been in effect for five years, since 2018 year 4 New additions to the reform of Hong Kong stock market regulations in the month 18A Since the beginning of this year, companies in fields such as innovative drugs, rare disease treatment, and high-tech medical devices have successively gone public in Hong Kong, leading to a major boom in the biotech sector of the Hong Kong stock market.   2023 year 5 month 17 Today, Frost & Sullivan,    LeadLeo Research Institute,   Live Report big data    ,   "TradeGo" co-authored with 2023 Hong Kong stocks for the year 18A The White Paper on the Development of Biotechnology Industry has been officially released. Frost & Sullivan Frost & Sullivan Dr. Wang Xin, Global Partner and Chairman of Frost & Sullivan Greater China, was interviewed by CBN to discuss 18A The development of biotech companies listed on the stock market since the implementation of the policy. CBN Q The analysis in the report 18A Among listed companies, which sectors or tracks have higher valuations? What are the commonalities behind these high valuations (including investment enthusiasm, company operations, etc.)?   Dr. Wang Xin   Global Partner and Chairman of Frost & Sullivan Greater China Region According to the division in our report 18A Biotech companies currently have relatively high valuations in the fields of cell therapy and oncology. Commonalities in the high valuations of these two tracks: 1 Investment enthusiasm: These two areas have received widespread attention and investment from investors, venture capital firms, private equity funds, etc., globally. The influx of capital is not only due to the high profitability potential of these areas but also because basic scientific theories have made relatively mature progress and technological breakthroughs are available. 2 Market demand: Against the backdrop of continuous growth in global healthcare market demand, this will support current biotech companies in expanding their marketing and product lines. There are better treatment methods for diseases faced by cell therapy or tumor treatment. Q What do you think 18A What are the technical attributes, maturity, and advancement of listed companies exactly?   Dr. Wang Xin   Global Partner and Chairman of Frost & Sullivan Greater China Region 18A The listed company focuses on biotechnology research and development and innovation, operating in fields such as biopharmaceuticals, medical devices, and cutting-edge technologies. Local pharmaceutical companies' innovation and R&D capabilities are gradually maturing and they are moving towards internationalization. 18A The listed companies in this sector are highly cutting-edge, with a diverse and inclusive portfolio ranging from small molecule targeted drugs, immunotherapy, cell genes, to mRNA Technology, from monoclonal antibodies, bispecific antibodies, PROTAC Oncolytic virus, ADC To bispecific ADC , from innovative drugs, innovative devices, innovative vaccines to CXO Fully covered. Leading companies such as BeiGene, Innovent Biologics, and Junshi Biosciences have already PD-1 The team is far ahead in the race track segment and is focusing more on innovative research and development on new tracks. Q What specific improvements are needed in the capital market environment to enable biotech companies to achieve sustainable and healthy development?   Dr. Wang Xin   Global Partner and Chairman of Frost & Sullivan Greater China Region 1 The healthy competition among new-generation biotech companies will bring new vitality to pharmaceutical innovation in our country. However, for sustainable and healthy development, it is necessary to promote differentiated innovation oriented towards clinical value to avoid homogeneous competition. At the same time, research and development (R&D) and financing plans need to be adjusted constantly. 2 Biotech companies face a long R&D cycle and high uncertainties, with the policies and trends of the capital market having a significant impact on their development. The standardized development of the capital market and the introduction of favorable new regulations are expected to promote further development of enterprises. 3 Primary and secondary markets need to have a deeper understanding and more sober valuation of the biotechnology industry. Attention to the biotechnology sector requires a long-term perspective to assist in the healthy development of biotech companies, reduce market vicious cycles, and avoid market backlash after bubbles burst.   * This interview was published in "CBN Business News". The reporter is    Zou Zhenjie    Original title is    "The    Released by Frost & Sullivan 18A Biotechnology Industry Report: The Valuation of the Cell and Tumor Therapy Track is the Highest    >>    (Click "Read Full Article" at the end of the text to read the complete report).

Global Food and Beverage Innovation Conference 5 month 14 - 16 day, by Foodaily Daily Food Hosted Foodaily FBIC The Global Food and Beverage Innovation Conference was held at the Shanghai Multinational Procurement Exhibition Center. With 'brand ecosystemization' as its core, this conference focused on 'youthfulness, digitalization, branding, and specialization', aiming at brands from 0 reach 1 , from B reach C With an open mindset, we have invited hundreds of heavyweight guests to share their insights. Together, we will discuss the new future of the food industry from an innovative perspective, helping the industry keep up with the pulse of the times and achieve innovative breakthroughs. The conference includes four major sections: conferences, exhibitions, awards, and special events. 360 Present innovative products, brands, industries, and new consumer trends in a 3D format. In addition to the traditional sessions of [Global Innovation Summit], [Dairy Products], [Catering], & Catering + 】、【Snacks & In addition to the Baking and Drinks forums, a special event, the [Channel Innovation Conference], and [Features] have been planned. + The [Food Innovation Conference] presented a grand event for the food and beverage industry.    Frost & Sullivan Frost & Sullivan As one of the conference's keynote speaker partners and content partners, Lou Lei, Executive Director of Frost & Sullivan Greater China, was invited to attend the conference and deliver a presentation titled 2023 Delivered a speech at "Insights into the Innovation Trends of China's Beverage Industry".   Executive Director, Greater China, Frost & Sullivan Lou Lei   Lou Lei said that judging from Frost & Sullivan's insights into the beverage industry in recent years,    Omni-channel, differentiated products, new media, and health concepts have become the new trend in the development of the entire industry at present.   Data shows, the soft drink market in China    The segment with the largest market size is packaged drinking water, and 2016 Year-end 2022 The annual average compound growth rate reaches 10% At the same time, functional beverages also maintain a high market share and growth rate. In addition, it is worth mentioning that although coffee beverages do not account for a large proportion, the entire coffee market has been growing rapidly in recent years. 2016 Year-end 2022 The annual average compound growth rate exceeds 24% .   In terms of channels,    Modern and traditional channels occupy 60% Market share: E-commerce channels continue to innovate, with interest e-commerce (content and social commerce) represented by Douyin, Kuaishou, Bilibili, WeChat, Weibo, and Rednote showing a rapid development trend.    It also brings continuous industry growth and new touchpoints.   From a product perspective, the beverage industry in China shows the following trends:   First, there is a trend towards sugar-free and healthy lifestyles.   The consumer group for this category is relatively young, and once a consumption habit is formed, repeat purchases will be very stable;   Second, packaging differentiation.     In terms of packaging style, there is a trend towards youthfulness and personalization. The brand is willing to attract more consumers' attention through cross-border collaborations, color visual impacts, etc. In terms of packaging appearance, it caters to the evolution of the 'single economy' towards lightweight, compact, and personalized packaging. At the same time, it innovates with fun and expands packaging functions to enhance product interactivity.   "In addition, environmental protection is also a focus for leading companies. By using environmentally friendly packaging, enterprises highlight their brand's sense of social responsibility and strengthen the brand's social value,"    In addition to focusing on environmentally friendly material packaging, many companies are starting to tell more stories about eco-friendly packaging. 'Lou Lei further explained that the beverage industry chain is a food sector with very high carbon emissions, which are currently mainly concentrated in packaging, production processes, and upstream raw materials. Some leading companies have begun to pursue carbon neutrality and peak carbon emissions, gradually widening the gap with small and medium-sized enterprises by setting higher standards for industry norms and enhancing their brand image. For example, carbon reduction in packaging, establishing zero-carbon factories, achieving product carbon neutrality, etc., these measures reflect the exemplary role of Chinese companies under the international trend of environmental protection and are also very important for companies going global to open up foreign markets.   Finally, Lou Lei pointed out that there is a trend towards product collaboration in the current hot spot of ready-to-drink tea with hot pot brewing.    For example, the cross-border collaboration between Wong Lo Kiu and Keen Yip's brands, targeting both The attribute of 'reducing internal heat and treating acne' resonates with consumers, combining seemingly unrelated categories to expand influence through contrast effects; Coca-Cola with PopMart, and Hito Tea with 'Dream of the Red Chamber'. IP address Collaboration, relying on with trends IP address Integration, with beverage companies continuously expanding their brand influence and user base.   "With consumers gradually developing a habit of consuming packaged beverages, how to innovate the brand to create new customers, new scenarios, and new markets has become a new direction of consumer demand," said Lou Lei.  

In April, Premier Li Qiang of the State Council proposed during a research visit to unicorn enterprises in Beijing that efforts should be made to explore new development areas and tracks, shape new drivers and advantages for development, and inject strong momentum into achieving overall improvement in economic operations and promoting high-quality development. 2023 China's Future Unicorn Top 100 The unicorn companies are concentrated in Beijing, Hangzhou, Shenzhen, Shanghai, etc., focusing on digital healthcare, artificial intelligence, new energy, advanced manufacturing, enterprise services, integrated circuits, metaverse, and new overseas expansion. 8 Large fields. In addition to established and well-known investment institutions, government-guided funds and industrial capital are accelerating their entry into the market. What factors have led to the regional distribution of unicorn enterprises being concentrated in Beijing, Shanghai, Guangzhou, and Shenzhen? Emerging fields such as digital healthcare, advanced manufacturing, and the metaverse are spawning unicorns. How will these contribute to high-quality economic development? What pain points do unicorn enterprises face in development, and can the capital market solve them? Overall, how effective is the current multi-level capital market in supporting unicorn enterprises?   How can future unicorn companies leverage the capital market to better develop new drivers and advantages? How can they guide listed companies in primary and secondary markets, as well as new sectors, to support the development of unicorn companies? Frost & Sullivan Frost & Sullivan Lu Jing, Partner and Managing Director of Frost & Sullivan's Greater China Region (hereinafter referred to as 'Frost & Sullivan'), was interviewed by Securities Daily to discuss unicorn enterprise development. Securities Daily Q Securities Daily Reporter: What factors have led to the regional distribution of unicorn companies being concentrated in Beijing, Shanghai, Guangzhou, and Shenzhen? Emerging fields such as digital healthcare, advanced manufacturing, and the metaverse are giving rise to unicorns. How will these help promote high-quality economic development? The degree of urban economic development, the ecosystem and atmosphere for entrepreneurship and innovation, the richness of talent resources, and the government's support for enterprises are key reasons why unicorn companies are concentrated in regions such as Beijing, Shanghai, Guangzhou, Shenzhen, and Hangzhou. Specifically, the degree of urban economic development benefits from the contributions made by these unicorn companies to economic growth. On the other hand, prosperous economic development also provides a favorable environment for the business development of these unicorn companies. 2022 cities each year GDP Look, Shanghai, Beijing, Shenzhen, Guangzhou, Hangzhou GDP Ranked first, second, third, fifth, and ninth in China, these cities represent typical new and old economic transitions in the country. The new driving force for economic growth is accelerating its formation and providing a broad development space for unicorn enterprises. The ecosystem and atmosphere for innovation and entrepreneurship are crucial for the development of unicorns. An excellent innovation and entrepreneurship ecosystem, along with a favorable atmosphere, not only promotes exchanges and cooperation among different enterprises but also facilitates communication between unicorn companies and investment institutions, providing an important foundation for continuous innovation momentum. Taking Beijing as an example, Zhongguancun in Beijing is home to a group of entrepreneurs and innovators who are brave in innovation and risk-taking. The rich scientific and educational resources and the strong industry-university-research platform have given rise to a large number of cutting-edge technologies, giving birth to a group of unicorn companies. Shenzhen is also often praised as an entrepreneurial city, surrounded by Tencent's ecosystem, which has fertile ground for innovation and entrepreneurship and is highly attractive to entrepreneurial talents. Cities with a high level of economic development and a good entrepreneurial innovation ecosystem and atmosphere are usually more able to attract outstanding talents from various fields, especially technical talents. Talents are an important factor for unicorn companies to continuously innovate and develop forward. Finally, government policy guidance and support for different industries, as well as the requirements in industrial development planning for optimizing the entrepreneurial innovation environment, provide an important foundation for entrepreneurs in terms of capital expenditure, tax incentives, technological innovation, and industrial linkage. Looking back at China's past development, it can be seen that in the past, economic development determined technological development. However, now it will be the other way around: technological development determines economic development. The most direct manifestation is China's emphasis on the development of digital economy. Emerging fields such as digital healthcare, advanced manufacturing, and metaverse, which integrate technologies like artificial intelligence, big data, cloud computing, and blockchain, are all new engines for digital economy development. 2021 In China, the scale of the digital economy reached 45.5 trillion yuan, proportion GDP only 40% It is expected that emerging fields will continue to drive the development of China's digital economy in the future, deeply integrating with the real economy and promoting the prospects of China's economy.   Securities Daily Reporter: What pain points do unicorn companies face in development, and can the capital market solve them? Overall, how effective is the current multi-level capital market in supporting unicorn companies? Looking back at the development of unicorn enterprises in the past, most of them are model innovation companies rather than technology innovation companies. Typically, unicorn enterprises with model innovation do not have high technical barriers and need to expand their scale effect through capital drive. Therefore, these companies often test their financing capabilities more severely. Before going public, unicorn enterprises usually need to go through multiple rounds of investment from venture capital and private equity investment institutions. When venture capital and private equity institutions face pressure to exit their funds, unicorn enterprises will then face subsequent capital pressures. With the establishment of China's multi-level capital market, especially the launch and operation of the ChiNext, STAR Market, and Beijing Stock Exchange, as well as the implementation of the Hong Kong stock market's listing mechanism for new technology and special-purpose companies, it has provided necessary support for unicorn enterprises' financing. It has also established more convenient exit channels for venture capital and private equity institutions, playing an important role in China's industrial structure adjustment, resource allocation optimization, and the improvement of financial market efficiency. Q Securities Daily Reporter: How can unicorn enterprises leverage the capital market to better develop new drivers and advantages in the future? How can we guide listed companies in primary, secondary markets, as well as new sectors, to support the development of unicorn enterprises? The vitality of the capital market cannot be separated from unicorn enterprises, and the development of unicorn enterprises also requires support from the capital market. Unicorn enterprises should make full use of China's multi-level capital market structure, expand their operational scale while establishing a response to the national call for building internationally leading scientific and technological innovation technologies in the '14th Five-Year Plan', strengthen their own technology research and development capabilities, and create a sustainable blueprint for their own development by establishing technical barriers. At the same time, they should actively encourage support for unicorn enterprises through measures such as tax incentives for investments in specific fields by listed companies in primary and secondary markets and new sectors.   * This interview was published in Securities Daily, with reporters Wu Xiaolu and Mao Yirong.   Original title is    "The    Empowering the capital market Supports unicorn enterprises in developing more "unique skills".    >>    (Click "Read Full Article" at the end of the text to read the complete report).

Fudan Fuhua goes public 30 Anniversary Celebration 5 month 10 Today, "At thirty, one stands firm and youth is at its prime Set sail for a new journey ” Fudan Fuhua goes public 30 The anniversary celebration ceremony was officially held in Shanghai. Dr. Wang Xin, Global Partner at Frost & Sullivan and Chairman of the Greater China Region, as well as Founder and Chairman of LeadLeo, was invited to attend the ceremony and deliver a speech. Shanghai Fudan Fuhua Science and Technology Co., Ltd. was established in 1993 year 1 It was listed on the Shanghai Stock Exchange in January and is the first listed company among national universities. ( Securities Code: 600624) . Over the past thirty years since its listing, relying on Fudan University and its advantageous disciplines, the company has successfully established a technology industry system centered around biomedicine, digital economy, and high-tech parks in its exploration and practice of 'developing high-tech and realizing industrialization'.     2023 The year marked the listing of Fudan Fuhua 30 On this historic occasion, Frost & Sullivan and LeadLeo extend their most sincere congratulations to Fudan Fuhua! 5 month 10 On the same day, Dr. Wang Xin, Global Partner at Frost & Sullivan and Chairman of the Greater China Region, Founder and Chairman of LeadLeo, was invited to speak at the listing event of Fudan Fuhua. 30 At this exciting historical moment, Dr. Wang Xin, on behalf of Frost & Sullivan and LeadLeo, extends his most sincere congratulations to Fudan Fuhua. Dr. Wang Xin said, 62 Since its establishment in [year], Frost & Sullivan has been deeply involved in global capital markets and corporate consulting services, witnessing and accompanying the growth and success of nearly ten thousand enterprises worldwide. It has helped outstanding listed companies such as Fudan Fuhua firmly establish themselves as benchmarks in growth, innovation, and leadership within their industries. At the same time, Frost & Sullivan has joined hands with LeadLeo to assist numerous enterprises in identifying their positioning, enhancing their value, and telling their capital market stories effectively, achieving efficient communication with investment institutions, investors, industry affiliates, stakeholders, and other parties involved. Dr. Wang Xin pointed out that Fudan Fuhua is one of the earliest listed companies in China and an important representative of the successful integration of science and technology with the capital market among Chinese universities, known as 'the first stock of Chinese universities'.    Frost & Sullivan and LeadLeo   Always closely monitor the vigorous development process of Fudan Fuhua and the latest trends in the industry where the company operates.   in the past 30 In the year, Fudan Fuhua has been continuously overcoming difficulties and pioneering innovation. It has not only achieved remarkable accomplishments in fields such as biomedicine, digital economy, and high-tech parks but has also actively integrated into the development of Fengxian District's industrial economy.   Fudan Fuhua has proven its strength through value creation and has actively returned value to investors and society, taking responsibility and fulfilling its mission without any regrets, truly setting an example for outstanding enterprises. We admire our partners who understand the path to corporate growth immensely!" said Dr. Wang Xin.   Dr. Wang Xin further stated that in the process of cooperation and exchange, Chairman Chu Jianping and the team at Fudan Fuhua are always inspiring us with their practical spirit and innovative drive.   In the future, Frost & Sullivan and LeadLeo will continue to cooperate sincerely with Fudan Fuhua to achieve win-win results and progress together. They will help Fudan Fuhua achieve high-quality and sustainable development over a longer period, achieve leapfrog new growth, and create a brighter future.   With the joint efforts of both parties, Fudan Fuhua will continue to lead the industry at the forefront. Stand proudly among the world's top-tier enterprises as a model of Chinese business. Finally, Frost & Sullivan and LeadLeo once again sincerely wish Fudan Fuhua a long and prosperous career, bright prospects, outstanding performance, and continuous progress!

Recently, the General Office of the CPC Central Committee and the General Office of the State Council issued the "Opinions on Further Improving the Medical and Health Service System," clearly requiring strengthening the development and capacity building of clinical medicine, public health, and medical device research and development systems, and accelerating the filling of gaps in high-end medical equipment. In the post-pandemic era, the market's demand for innovative iterations of medical products has also been strong, bringing about historic development opportunities for the innovative medical device industry. "Integrate Medical Innovation, Create a Healthy Future", co-hosted by Binlingxing Venture Capital and Artery Network 2023 The 7th Future Medicine Conference 100 The Strong Conference Sub-forum - Cross-disciplinary Technology Clinical Application Forum of Medical Devices will be held on 2023 year 5 month 5 The conference was successfully held in Shanghai on the 1st.   The forum aims to strengthen the linkage of industry, academia, research, and medicine, promote interdisciplinary exchanges, integrate perspectives from different angles such as clinical practice, technology, and market, empower innovative thinking in industrial integration, jointly explore the possibility of technological innovation breakthroughs that transcend existing scientific and technical boundaries in medical devices, and their potential value in addressing major clinical issues. On the forum, several industry experts, clinicians, and nearly 20 Medical device entrepreneurs discussed in depth the development and application trends of technological innovation in the medical device industry. The keynote speeches at the conference explored how to "promote global innovation into clinical practice in China through multi-party cooperation," "innovation practices based on clinical needs," and investigated "the path of innovative device development in China." Subsequently, the participating guests engaged in three roundtable discussions around hot topics such as innovative technology platforms for major diseases, clinical applications of interdisciplinary technological innovation, and intelligent and automated trends, engaging in in-depth views exchange and technical communication. Swipe left and right to view more photos from the event Sun Xiaolu, a partner at Binjiang Venture Capital, attended the forum and delivered an opening speech;   Shen Li, Chief Physician of the Department of Cardiology at Zhongshan Hospital Affiliated to Fudan University and Director of the Office of the National Clinical Research Center for Radiation and Therapy, attended the event and delivered a keynote speech titled 'Innovative Practices Based on Clinical Needs'.   Frost & Sullivan Frost & Sullivan Mao Hua, Partner and Managing Director of Frost & Sullivan's Greater China Region, attended the event and delivered a speech on “    Delivered a keynote speech on "Exploration of the Development Path of Innovative Medical Devices in China";     Binjiang Star Venture Capital Partners Li Zhe, Kangfeng Biology CEO Zhu Jun and Wang Zhengbin, Managing Director of Binlinxing Venture Capital, attended the meeting and presided over roundtable forums respectively; He Yuping, Founder of Dunbo Medical, Zhang Ruian, Deputy General Manager of Jianshi Technology, Lifeshield Medical Chen Zulin, General Manager of Life Shield Medical China; Li Yunxiang, Founder of NanoViz; Wang Yongsheng, General Manager of Weiqiang Medical; Le Bin, Founder of Yichao Medical; Chen Shixing, Co-founder of ChaoGuang Micro Medical; Xu Tianrui, Founder of Lingchuang Medical Valley; Wang Zhengbin, Director of Puluo Medical; Ruidi Biotechnology CFO Xu Yingrui, Founder of Ruining Biotechnology, Pan Zhen, Founder of Dawan Biotechnology CEO Co-founder and co-founder-in-chief Chen Liang, DaRong Technology CEO Zhou Yu, Hanzandi CMO He Dan, Zhu Jianjun, the AI R&D Director at Hengle Technology, and Wang Zhen, the founder of Vision Medical, along with other founders of medical device companies invested by Bilingxing Venture Capital, attended the meeting and participated in roundtable discussions; the forum was chaired by Sun Shanshan, the Executive Director of Bilingxing Venture Capital. Partner and Managing Director of Frost & Sullivan Greater China Region fattening Mao Hua said,   China's medical device market size ranks second globally, but per capita consumption is far lower than that of the United States, leaving significant room for development. He pointed out that    Medical devices belong to the high-end manufacturing industry and require innovative development along with manufacturing collaboration. Manufacturing is one of China's strongest fields and already possesses considerable competitive advantages. In the future, after catching up in technological innovation, China's medical device industry will shift from the past imitation model to independent innovation and further towards globalization. Looking at the sub-sectors of medical devices, cardiovascular intervention, robotics, and imaging have become the most favored areas for capital investment, consistently ranking among the top in terms of investment and financing transactions for three consecutive years. Top 3 The field of cardiovascular intervention is undergoing innovation in multiple dimensions such as procedures, materials, and technology. The era of robotics is subverting various traditional surgeries and presenting trends towards informatization, intelligence, minimally invasive techniques, etc. In the field of medical imaging, big data, intelligence AI The application trend of intraoperative image fusion technology is significant. Mao Hua's detailed data analysis points out that strong policy support, active capital assistance, the return of outstanding talents, and diverse innovation models are the fundamental driving forces behind the rapid development of innovative medical devices in China. In the primary market, early investment in platforms, incubation, and niche areas is favored. In the secondary market, companies choose to go public with more diversification, valuing commercial capabilities and their own self-sustaining abilities. This indicates that investment and financing in innovative medical devices are returning to rationality. Focusing on clinical pain points, capturing the world's most cutting-edge technologies, and combining precision diagnosis and treatment with digitization will be important directions for future technological innovation. The characteristics of medical devices determine their diverse sub-sectors and tracks, requiring investment to value the integrity of the industrial chain more, layout core components and key raw materials, and place more emphasis on R&D, cooperation, and business model diversification. About Frost & Sullivan's Healthcare Practice The Healthcare Practice of Frost & Sullivan has professional analytical capabilities and extensive project experience in the life sciences. Leveraging Frost & Sullivan's global think tank resources and cross-industry business development platform in Greater China, Frost & Sullivan Healthcare has unique core advantages in healthcare industry investment and financing services. Frost & Sullivan Healthcare has a wide range of corporate clients in China and in the past 20 In the year, a vast customer network was established, and a wealth of project experience in various medical sub-fields was accumulated. Project types include Knowledge Center projects (in-depth content, promotional activities). Pre-IPO financing project DCF model Valuation, Business Plan Services), IPO listing We provide listed projects (industry consulting, clinical audits, fundraising and investment writing), market research, market value management, strategic consulting, etc. We also cooperate with well-known domestic and international information platforms and investment and financing institutions to provide one-stop solutions for enterprises in specialized sub-fields such as pharmaceuticals and medical devices. Our services have received wide attention from investors.

car MCU The field has long been dominated by overseas oligarchs. How can domestic automotive chips break through?   From the horizon to black sesame seeds, how does one assess the current development stage and trend of domestic in-vehicle chips? AI Can the chip become a breakthrough point?    Some automaker supply chain manufacturers have stated that they are currently experimenting with partnerships with Horizon Robotics and Black Sesame, but Qualcomm and NVIDIA remain their preferred choices. What is your view on the issue of domestic automotive chip substitution? Do they have an advantage in terms of technology and price?   Frost & Sullivan Frost & Sullivan The executive director of Frost & Sullivan's Greater China region, Mr. Xiang Wei, was interviewed by South China Morning Post to discuss the current development status of domestic in-vehicle chips. Nanhua Morning Post Q car MCU The field has long been dominated by overseas oligarchs. How can domestic automotive chips break through? Relying on their first-mover advantage, overseas leaders have formed technical accumulation and obtained long-term reliability certifications, capturing most MCU Market share. In the short term, to break through the predicament, domestic automotive chip manufacturers need to seize the opportunity for domestic substitution and actively enter the supply chain of vehicle manufacturers. At the same time, domestic manufacturers should also strengthen close cooperation with customers in the form of an ecosystem to accelerate the improvement of their influence in automotive-grade technology, products, or solutions. Establishing a product ecosystem can not only help domestic manufacturers quickly respond to customer needs and usage feedback, form differentiated products and solutions, increase customer loyalty, but also help improve domestic manufacturers' capabilities in high-end automotive-grade applications, achieving long-term development for the industry as a whole. Chip design and production line technology need to advance simultaneously, and manufacturers also need to cooperate deeply with foundries and packaging and testing processes to accelerate the introduction of new technologies and products to meet high-end application needs. Q From the horizon to black sesame seeds, what is your view on the current development stage and trend of domestic in-vehicle chips? AI Can the chip become a breakthrough point?   With the further development of automotive intelligence, chips in related fields such as autonomous driving and intelligent cockpits are experiencing rapid development. Market giants at home and abroad have flocked to this sector, concentrating on high-end chips. Currently, at the chip level, the shortage of chips by automakers has led to a surge in business for many domestic chip companies. There are numerous players in the automotive chip market, with complex chip architectures. Chips in the fields of intelligent driving and intelligent cockpits are developing towards greater computing power. AI The chip is known as AI Accelerators or computing cards, specifically designed for acceleration AI Modules for a large number of compute tasks in applications. In traditional MCU In the case where intelligent driving requirements are difficult to meet, AI The importance of chips is becoming increasingly prominent. At this stage, they are used for automotive decision-making control AI Chips take data, computing power, and algorithms as their three major elements. In the complex vehicle operation environment, in-vehicle chips also pay great attention to the utilization rate of computing power. Due to AI The algorithm requires a large amount of data exchange with memory, so currently, memory and bandwidth are important factors restricting the utilization rate of computing power and will also be the focus for major manufacturers to advance and break through. Currently, intelligent driving has been elevated to the national policy level and is key to the transformation and upgrading of China's automotive industry. Technological iteration and strong support from policy aspects will assist in the development of automobiles. AI Chips have become a hot topic in the new energy vehicle market. Q Some automaker supply chain manufacturers have stated that they are currently experimenting with partnerships with Horizon Robotics and Black Sesame, but Qualcomm and NVIDIA remain their top choices. What's your opinion on the issue of domestic automotive chip substitution? Do they have an advantage in terms of technology and price? Computing power determines the intelligence level of autonomous vehicles. For domestic in-vehicle chips to compete with traditional chip manufacturers that have made breakthroughs in automotive-grade certification, they need to demonstrate their company's uniqueness and advantages in computing power, application technology, and cost-effectiveness. Firstly, enhancing effective computing power will become the core competitiveness of in-vehicle chips. To support future autonomous vehicles in OTA The continuous rise in computing power demand brought about by software and algorithm upgrades will become a focus, supporting the vast number of computing power applications. Secondly, domestic automotive chip companies are gradually deepening their technical expertise, forming a complete set of self-developed technologies. IP address In addition to the HPC application toolchain, we exclusively develop algorithm solutions for domestic and international automakers, providing more detailed technical support. Compared to traditional chip manufacturers, domestic automotive chip companies possess more software tools, making customer operations more convenient and offering customized technical advantages. Finally, domestic automotive chips offer extremely high cost-effectiveness among automotive-grade chips of the same level and quality. Additionally, the product deployment speed and team investment are a notch above traditional chip manufacturers. In the early stages of the market, more reasonable prices, faster deployment speed, and deeper investment have ensured the product and business model planning of domestic automotive chip manufacturers, facilitating resource aggregation and accelerating domestic substitution.   * This interview was published in South China Morning Post, with the reporter being Tracy Qu Original title:    "The    The boom in smart vehicles is driving Chinese automakers and third-party manufacturers such as Black Sesame to ramp up auto chip output    >>    (Click "Read Full Article" at the end of the text to read the complete report).